UPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD
|
|
- Randell Robertson
- 5 years ago
- Views:
Transcription
1 UPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD
2 DISCLOSURE Speaker s bureau: Pharmacyclics, Janssen, Seattle Genetics, Astra Zeneca Consultant: Juno therapeutics, Astra Zeneca, BeiGene, Pharmacyclics
3 Epidemiology Chronic lymphocytic leukemia (CLL) is a low grade leukemic lymphocytic lymphoma; small lymphocytic lymphoma (SLL) is a nodal form of the same disease CLL/SLL is the most common hematological malignancy in the Western world; incidence is ~5/100,000 persons per year in the US Median age at diagnosis ~72 years Male predominance; higher in Caucasians ~10% patients with a family history of some lymphoma Exact etiology is unknown Muller-Hermlink HK, et al. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours in Haematopoietic and Lymphoid Tissues. Lyon, France. IARC press, 2001:
4 Diagnosis and workup Rule out masquerading other lymphoma Incidental diagnosis History and physical examination; trend of CBCs; B symptoms (fever, night sweats, unexplained weight loss); severe fatigue Review CBC/differential, peripheral blood smear, flow cytometry/immunophenotyping: peripheral blood lymphocytosis with the presence of 5000 monoclonal B- cells/ul is required Bone marrow biopsy typically not needed for diagnosis
5 Monoclonal B-lymphocytosis (MBL) Presence of monoclonal lymphocytosis but with <5000 B- cells/ul in the peripheral blood and no accompanying lymphadenopathy or organomegaly by physical examination or radiographical imaging, cytopenias or disease-related symptoms is defined as MBL Incidence in the US is 3% Progression to CLL/SLL can 1-2% per year
6 Prognostic markers in CLL/SLL Cytogenetics: Del13q Trisomy 12 Normal Del11q Del17p Del6q TP53 mutations Notch1 mutations SF3B1 mutations IGHV mutation status ZAP70 CD38 Lymphocyte doubling time (LDT) β2 microglobulin Stage of disease by Rai or Binet staging
7 CLL Staging Rai stage Risk category Clinical features 0 Low Lymphocytosis alone 1 Intermediate Lymphadenopathy 2 Intermediate Hepato/splenomegaly 3 High Anemia (<11g/dl) 4 High Thrombocytopenia (<100,000/L) Binet stage A B C Clinical features HGB 10 g/dl, platelets 100/L, <3 areas of lymphadenopathy/ organomegaly* HGB 10 g/dl, platelets 100/L, 3 areas of lymphadenopathy/ organomegaly* Anemia (<10g/dl), thrombocytopenia (<100,000/L), or both *nodal areas: cervical [head and neck], axillary, inguinal (including femoral lymph nodes), spleen, liver
8 Who needs treatment? International workshop on CLL (iwcll) guidelines for treatment initiation Hallek M, et al. Blood :
9 iwcll guidelines for treatment initiation progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia massive ( 6cm below left subcostal margin), progressive, or symptomatic splenomegaly massive ( 10cm in longest diameter), progressive, or symptomatic lymphadenopathy progressive lymphocytosis with an increase of >50% over a 2 month period or LDT of <6 months autoimmune hemolytic anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy constitutional symptoms defined as 1 of the following: (i) unintentional weight loss of 10% within the previous 6months (ii) significant fatigue (ECOG PS 2;inability to work or perform usual activities) (iii) fevers >100.5F or 38C for 2 weeks without other evidence of infection (iv) night sweats for >1 month without evidence of infection
10 Frontline therapeutic options
11 German CLL study group (GCLLSG): frontline treatment CLL4 study: FC vs. fludarabine alone CLL8 study: FCR vs. FC Subgroup with exceptionally good outcome has right age/fitness, mutated IGHV genes and no del17p/del11q (plateau after 4 yrs; MRD neg 6 yrs later) Eichhorst BF, et al. Hematol J 2006; 107: Hallek M, et al. Lancet 2010; 376: Eichhorst B, et al. Blood 2014; 124: abs.19
12 CLL8 study: FCR vs. FC
13 ASH2016 MDACC experience with FCR Thompson et al., Blood, 2016
14 German CLL study group (GCLLSG): frontline treatment CLL4 study: FC vs. fludarabine alone CLL8 study: FCR vs. FC Subgroup with exceptionally good outcome has right age/fitness, mutated IGHV genes and no del17p/del11q (plateau after 4 yrs; MRD neg 6 yrs later) CLL10 study: FCR vs. BR Eichhorst BF, et al. Hematol J 2006; 107: Hallek M, et al. Lancet 2010; 376: Eichhorst B, et al. Blood 2014; 124: abs.19
15 CLL10: FCR vs. BR Phase 3 randomized trial, fit CLL patients (ages yrs) with advanced stage disease, previously untreated, no 17p deletion N = 564; 6 cycles of either regimen; median followup 37.1 months FCR BR P-value ORR 95% 96% 1.0 CR 40% 31% [higher MRD negative CRs in FCR arm] Median PFS 55.2 months 41.7 months [better in <65 years old] OS at 3 years 91% 92% Severe neutropenia Severe infections 84% 59% < % 25% [especially in older pts] Eichhorst B, et al. Lancet Oncol 2016; 17:
16 CLL Disease Progression Curve Minimal residual disease (MRD) defined cutoff Adapted from:
17 Targeted therapies
18 Ibrutinib FDA approved Ph1b/2 study of 85 CLL pts, mostly high risk ORR of 71% (2 CR, 34 PR) % PR-L At 26 months, estimated PFS was 75% and OS 83% Well tolerated Byrd JC, et al. N Engl J Med 2013; 369: 32-42
19 Ibrutinib: RESONATE trial Phase 3 trial of ibrutinib (420mg po daily) vs. ofatumumab in r/r CLL N = 391 ORR 42.6% (+20% PR-L) vs. 4.1% (p<0.001) Median PFS not reached (88% PFS at 6 months) vs. 8.1 months (p<0.001) At 12 months, OS 90% (ibru) vs. 81% (ofa) (p=0.005) Byrd JC, et al. N Engl J Med 2014; 371:
20 RESONATE trial: 5 year update Progression-Free Survival Overall Survival Median PFS 5-year PFS TN (n=31) NR 92% R/R (n=101) 52 mo 43% Median OS 5-year OS TN (n=31) NR 92% R/R (n=101) NR 57% NR, not reached. 5-year update, O Brien et al. ASH 2016
21 Best Response in Patients With High-Risk Abnormalities 100% 80% 60% R/R del11q (n=35) 97% 9% R/R Unmutated IGHV (n=79) 90% R/R Complex Karyotype (n=41) 90% 9% 7% R/R del17p (n=34) 79% 6% CR PR PR-L 40% 86% 77% 76% 65% 20% 3% 4% 7% 9% 0% Median DOR, 38.7 (0.0+ to 65.3+) 53.2 (0.0+ to 65.5+) 38.7 (0.0+ to 65.5+) 30.6 (0.0+ to 65.3+) months (range) Median followup, months 55 (1+ 67) 49 (1+ 67) 55 (1 67) 47 (1 67) (range) NR, not reached. 5-year update, O Brien et al. ASH 2016
22 Ibrutinib: RESONATE-2 trial Ph3, international, open label, randomized trial of ibrutinib vs. chlorambucil in previously untreated older CLL/SLL patients N = 269 Median age = 73 years ORR 86% vs. 35% (p<0.001) Significant improvement in EFS, PFS and OS with single agent ibrutinib compared to Clb Burger JA, et al. N Engl J Med 2015 Dec 17;373(25):
23 RESONATE-2 update PFS was significantly improved for ibrutinib across high-risk subgroups, including del11q and unmutated IGHV gene OS analysis resulted in 2-yr survival rate estimates of 95% (ibr) vs. 84% (clb) ORR was 92% with ibr vs 36% with clb (P<0.0001); CR/CRi within the ibr arm improved from 11% at 18.4 mo to 18% with longer follow-up of 28.6-mo RESONATE-2 update, Barr et al.ash2016
24 Other targeted therapies Idelalisib - FDA approved but further trials halted due to toxicities Copanlisib FDA approved for rel/ref CLL; IV Duvelisib - FDA approved for rel/ref CLL Umbralisib Phase 3 trials ongoing in CLL; much better safety profile Venetoclax FDA approved in del17p CLL and rel/ref CLL Acalabrutinib in phase 3 trials ongoing in CLL; FDA approved for mantle cell lymphoma Zanubrutinib studies ongoing in MCL, MZL, CLL, WM
25 ASH 2018 update (frontline therapies)
26 Abstract 6 Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A phase 3 study comparing BR (Arm 1) with ibrutinib (Arm 2) and the combination of ibrutinib plus rituximab (Arm 3) age 65 years with previously untreated, symptomatic CLL Between 12/9/2013 and 5/16/2016, 547 pts were registered and randomized (Arms 1: 183, 2: 182, and 3: 182) Median age=71 years; 67% were men High-risk Rai stage (stage III/IV) was seen in 54%, unmethylated Zap-70 in 53%, and del(17p) or del(11q) by local FISH in 28% median follow-up of 32 months Woyach J, et al. ASH 2018
27 Abstract 6 ( cont.): median PFS was 41 mo in Arm 1 and has not been reached in Arms 2 or 3 (Arm 2 to 1 p<0.0001; Arm 3 to 1 p<0.0001; Arm 3 to 2 p=0.48) ibrutinib produces superior PFS to standard CIT in older pts with CLL and justifies it as a standard of care treatment for pts age 65 and older. The addition of rituximab does not prolong PFS with ibrutinib. Woyach J, et al. ASH 2018
28 Abstract 6 (cont.): no significant differences in OS among arms (p=0.87), median OS has not been reached for any arm, and 2-year OS estimates were 95%, 90%, and 94% in Arms 1, 2, and 3, respectively Grade 3+ treatment-emergent AEs were seen in 428 of 537 evaluable pts with 61%, 41%, and 38% of pts experiencing Grade 3+ heme AEs (p<0.0001) and 60%, 72%, and 71% of pts experiencing Grade 3+ non-heme AEs (p=0.03) in Arms 1, 2, and 3 respectively Grade 5 AEs were seen in 5 (2.8%), 14 (7.8%), and 14 (7.7%) pts (p=0.07); unexplained or unwitnessed death was seen in 2 (1.1%), 7 (3.9%), and 4 (2.2%) pts (p=0.24) in Arms 1, 2, and 3 respectively Woyach J, et al. ASH 2018
29 Abstract 691 Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 illuminate international, open-label, randomized phase 3 study previously untreated CLL/SLL requiring treatment 65 years of age or were <65 years old with coexisting conditions (Cumulative Illness Rating Scale score >6, creatinine clearance <70 ml/min, and/or del(17p) or TP53 mutation) 229 pts randomized 1:1 to receive ibr (420 mg once daily continuously) with G for a total of 6 cycles (n=113), or clb with G for 6 cycles (n=116) Median age = 71 years (range, 40-87) 65% of pts had high-risk genomic features median follow-up = 31.3 mo Moreno C, et al. ASH 2018
30 Abstract 691 (cont.): Ibr-G resulted in superior PFS compared with clb-g (median not reached [NR] vs 19.0 mo (P<0.0001) PFS benefit with ibr-g was consistent across subgroups examined Response rates and depth of remission (CR and undetectable MRD) were also higher with ibr-g Combination therapy with ibr-g was tolerable With ~3 yrs of follow-up, 70% of pts in the ibr-g arm remain on single-agent ibr Moreno C, et al. ASH 2018
31 Late Breaker Abstract-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912) treatment-naive individuals with CLL who were age 70 and required therapy Patients with deletion 17p- were excluded 529 pts were randomized in a 2:1 ratio to receive ibrutinib (420 mg/day until disease progression) and rituximab for 6 cycles starting in cycle 2 (n = 354) OR 6 courses of intravenous FCR (n = 175) 19 patients did not start protocol therapy median follow-up of 33.4 months Shanafelt T, et al. ASH 2018
32 LBA-4 (cont.): The combination of ibrutinib and rituximab provides superior PFS (p<0.0001) and OS (p<0.0003) relative to FCR for patients with previously untreated CLL age 70 Shanafelt T, et al. ASH 2018
33 LBA-4 (cont.): Superior PFS for IR was independent of age, sex, performance status, disease stage or the presence/absence of del11q23 IR was also superior to FCR for IGHV unmutated patients (p<0.0001) but not IGHV mutated patients (p=0.07) FCR was more frequently associated with grade 3 and 4 neutropenia (FCR: 44% vs. IR: [23%]; p<0 0001) and infectious complications (FCR: 17.7% vs. IR: 7.1%; p<0.0001) Shanafelt T, et al. ASH 2018
34 Ibrutinib+FCG (MDACC) Dr. Nitin Jain Ph2 study in younger, previously untreated patients with IGHV-M N=43 (1 was later found to have IGHV-U); med age 60 yrs; no del(17p)/ TP53 mutation ifcg x 3 cycles and time limited ibrutinib; median followup 18.6 mo ORR 100% at 3 months (17 CR/Cri, all MRD-U; 25 PR); 38/42 (90%) achieved U-MRD in BM at 3 months Responses continue to improve over time (6 months (n=35): CR/CRi 74%, U-MRD 94%; 12 months (n=28): CR/CRi 86%, U-MRD 100%) All 28 pts who reached the 12 month time-point were U-MRD and stopped ibr; all 28 maintain U-MRD status at a median follow-up of 10.1 months (range, ) after stopping ibr without progression ifcg achieves high rate of U-MRD in previously-untreated patients with CLL with IGHV-M CLL. No patient has progressed and all patients who have stopped ibrutinib maintain U-MRD status. Manageable toxicities
35 Ibrutinib + venetoclax (MDACC) Dr. Nitin Jain Phase 2 trial in previously unteated and rel/ref CLL Previously untreated cohort = 80; median age was 65 yrs (26-83) All pts had at least one high-risk feature: del(17p), mutated TP53, del(11q), unmutated IGHV, or age 65 years (yrs) Ibrutinib x3 cycles then venetoclax ramp up started Ibrutinib continues indefinitely if MRD positive BM at 2 yrs but venetoclax stops at 2 yrs median follow-up = 9.6 months After 3 months of IBR monotherapy, the majority pts were in PR; after addition of VEN, increasing proportions of pts achieved CR/CRi and BM U-MRD remission; no pt has had CLL progression Responses were noted in older adults and across all high-risk subgroups Adverse event profile was similar to what has been reported individually with IBR and VEN.
36 Relapsed/refractory therapeutic options
37 Murano trial update: ASH Dr. John Seymour Venetoclax + rituximab (VR) vs. BR x6 cycles [V continued for 2 yrs] Randomized ph3 trial for rel/ref CLL 389 pts were enrolled in VenR (n=194) or BR (n=195) arms superior PFS of VenR over BR shown in ASH 2017 Med followup now 36 months With all pts off treatment, continued substantial benefit was observed with VenR, with PFS and OS superior to BR no new safety signals; most pts were able to complete treatment. rate of CLL progression in the first 12 mo after Ven completion was modest (13%), supporting the feasibility and safety of a time-limited VenR duration
38 Ibrutinib + venetoclax (CLARITY trial) Dr. Peter Hillmen Ph2 trial N = 54 10/51 (20%) of patients had 17p del, 13/54 (25%) 11q del (but not 17p), and 40/53 (75%) had unmutated IGVH genes Ibrutinib for 8 weeks then venetoclax ramp up Stopping options built in if MRD neg After 6 months of combined ibrutinib plus venetoclax, undetectable MRD was achieved in 19/49 (39%) patients in peripheral blood (PB) and 12/49 (24%) in bone marrow (BM) After 12 months of combined therapy all patients had responded by IWCLL criteria and 23/40 (58%) had achieved a complete remission (CR or CRi) undetectable MRD (MRD4) was achieved in 23/40 (58%) patients in PB and 17/41 (41%) in BM
39 Cellular therapy Allogeneic hematopoietic cell transplantation N=694 (retrospective) High risk disease 2 yr-nrm 28% 5 yr EFS 37% CAR-T cells Schetelig J, et al. ASH 2015 abs
40 CD19 specific CAR-T cells in CLL N = 14; median cell dose = 7.5x10^8 cells 4 CRs (29%), 4 (29%) PRs, ORR 57% CAR-T cells detectable 3 yrs later in some Ph2 randomized study ongoing to determine best cell dose (n=18, ORR 39%, CR 17%) Expected toxicities: B cell aplasia, delayed TLS and CRS Porter D, et al. Blood 2013; ASH abs Porter D, et al. Blood 2013; ASH abs. 873
41 CD19 CAR-T cells (JCAR014) in ibrutinib-refractory CLL N = 24, median age 60 yrs MTD 2x10^6 CAR-T cells/kg; CD8+:CD4+ CAR-T cells 1:1 19 ibrutinib ref, 3 ibrutinib intolerant, 2 had not progressed on ibrutinib; 6 were ref to venetoclax; 23 had complex karyotype and/or del17p 20 pts (83%) had CRS and 8 pts (33%) had neurotoxicity ORR at 1 month in 19 of 20 restaged pts who had received Flu/Cy and CAR-T cells was 74% (4/19 CR, 10/19 PR) 15/17 patients (88%) with marrow disease before CAR-T cells had no disease by flow cytometry after CAR-T cells; 12 underwent deep IGH sequencing and 7 had no malignant IGH sequences detected in marrow Absence of the malignant IGH clone in marrow of patients with CLL who responded by IWCLL criteria was associated with 100% progressionfree survival and overall survival (median 6.6 months follow-up) after CAR-T cell immunotherapy Turtle C, et al. J Clin Oncol 2017; 35 (26):
42 ASH ABSTRACT #300 Rapid MRD-negative Responses in Patients With Relapsed/Refractory CLL Treated With Liso-cel, a CD19-Directed CAR T-cell Product: Preliminary Results From TRANSCEND CLL 004, A Phase 1/2 Study Including Patients With High-risk Disease Previously Treated With Ibrutinib Tanya Siddiqi, 1 Jacob D. Soumerai, 2 William G. Wierda, 3 Jason A. Dubovsky, 4 Heidi H. Gillenwater, 4 Lucy Gong, 4 Alan Mitchell, 4 Jerill Thorpe, 4 Lin Yang, 4 Kathleen A. Dorritie 5 1 City of Hope National Medical Center, Duarte, CA, USA; 2 Center for Lymphoma, Massachusetts General Hospital, Boston, MA, USA; 3 The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4 Juno Therapeutics, a Celgene Company, Seattle, WA, USA; 5 University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
43 Transcend CLL 004 Phase 1 study design (NCT ) Key Eligibility Relapsed/refractory CLL/SLL Failed or ineligible for BTKi a High-risk disease b : failed 2 prior therapies Standard-risk disease: failed 3 prior therapies ECOG PS 0 1 Dose-escalation: mtpi-2 Design c 28-day DLT period Primary Objective Determine recommended dose Safety Exploratory Objectives Antitumor activity Pharmacokinetic profile Dose Level Dose Treated (N=16) CAR+ T cells CAR+ T cells CAR+ T cells 10 a Failure defined as SD or PD as best response, or PD after previous response, or discontinuation due to intolerance (unmanageable toxicity). Ineligibility defined as requirement for full-dose anticoagulation or history of arrhythmia. b Complex cytogenetics abnormalities, del(17p), TP53 mutation, or unmutated IGHV. c Guo W, Wang SJ, Yang S, et al. Contemp Clin Trials. 2017;58: BTKi, Bruton's tyrosine kinase inhibitor; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; DLT, doselimiting toxicity; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IGHV, immunoglobulin heavy chain variable region; mtpi, modified toxicity probability interval; PD, progressive disease; SD, stable disease; SLL, small lymphocytic lymphoma. Data on file 21 September Siddiqi T et al. ASH Abstract 300.
44 Baseline characteristics Characteristic All Patients (N=16) Age, median (range) y 64.5 (51 76) Male, n (%) 8 (50.0) Stage, n (%) Rai Stage III/IV 10 (62.5) Binet Stage C 10 (62.5) High-risk features (any), n (%) 12 (75.0) TP53 mutation 10 (62.5) Complex karyotype a 8 (50.0) Del (17p) 7 (43.8) Prior lines of therapy, median (range) 4.5 (2 11) Prior ibrutinib, n (%) 16 (100.0) Ibrutinib relapse/refractory, n (%) 13 (81.3) Ibrutinib progression and prior venetoclax, b n (%) 8 (50.0) a At least 3 chromosomal aberrations. b 7 patients progressed on venetoclax; 1 patient had best response of SD after 3 months of treatment. Siddiqi T et al. ASH Abstract 300.
45 Serious AEs All Patients (N=16) Any serious AEs of any grade, n (%) 7 (43.8) Lung infection 3 (18.8) Aphasia 1 (6.3) Blood fibrinogen decreased 1 (6.3) Encephalopathy 1 (6.3) Febrile neutropenia 1 (6.3) Hypertension a 1 (6.3) Hyponatremia 1 (6.3) a 1 DLT of grade 4 hypertension was reported in DL2. All serious AEs were of grade 3 and all were reversible Siddiqi T et al. ASH Abstract 300.
46 AEs of Special Interest (none were Grade 4/5) Total DL1 DL2 (N=16) (n=6) (n=10) CRS any grade, n (%) 12 (75.0) 6 (100.0) 6 (60.0) Median time to first onset, d (range) 6.5 (1 10) 6.5 (1 9) 5.0 (2 10) Median duration, d (range) 5.5 (2 30) 5.5 (3 30) 5.5 (2 13) Grade 3, n (%) 1 (6.3) 0 1 (10.0) Neurologic events (NE) a any grade, n (%) 6 (37.5) 2 (33.3) 4 (40.0) Median time to first onset, d (range) 10.0 (4 21) 16.0 (11 21) 8.0 (4 11) Median duration, d (range) 6.5 (2 20) 4.0 (2 6) 8.0 (3 20) Grade 3 b, n (%) 3 (18.8) 2 (33.3) 1 (10.0) Any, n (%) CRS or NE a 13 (81.3) 6 (100.0) 7 (70.0) CRS and NE a 5 (31.3) 2 (33.3) 3 (30.0) Tocilizumab and/or dexamethasone use 11 (68.8) 4 (66.7) 7 (70.0) Tumor lysis syndrome any grade, n (%) 2 (12.5) 1 (16.7) 1 (10.0) Grade 3, n (%) 2 (12.5) 1 (16.7) 1 (10.0) a Neurologic events are treatment-related events defined by the Investigator. b Encephalopathy n=1; aphasia n=1; confusional state and encephalopathy n=1. Siddiqi T et al. ASH Abstract 300.
47 Response Rates Total DL1 DL2 Best Overall Response, n (%) (N=16) (n=6) (n=10) ORR 13 (81.3) 6 (100.0) 7 (70.0) CR/CRi 7 (43.8) 5 (83.3) 2 (20.0) PR/nPR 6 (37.5) 1 (16.7) 5 (50.0) SD 2 (12.5) 0 2 (20.0) PD 1 (6.3) 0 1 (10.0) Total DL1 DL2 Response at 30 Days Post liso-cel, n (%) (N=16) (n=6) (n=10) ORR 12 (75.0) 6 (100.0) 6 (60.0) CR/CRi 5 (31.3) 3 (50.0) 2 (20.0) PR/nPR 7 (43.8) 3 (50.0) 4 (40.0) Response at 3 Months Post lisocel, n (%) (N=10) (n=6) (n=4) ORR 8 (80.0) 5 (83.3) 3 (75.0) CR/CRi 5 (50.0) 3 (50.0) 2 (50.0) PR/nPR 3 (30.0) 2 (33.3) 1 (25.0) Siddiqi T et al. ASH Abstract 300.
48 Phase 1 TRANSCEND CLL 004: Minimal Residual Disease 11 of 15 (73.3%) patients had umrd4 in blood by flow at day 30 All continue to remain undetectable at latest follow-up 5 patients have post-dose follow-up at month 6 Total DL1 DL2 Blood, flow (N = 15) (n = 6) (n = 9) umrd4 at any time point, n (%) 11 (73.3) 6 (100.0) 5 (55.6) Bone marrow, NGS (N = 8) (n = 5) (n = 3) umrd4 at any time point, n (%) 7 (87.5) 4 (80.0) 3 (100.0) All continue to maintain umrd4 response (CR, n = 4 and PR, n = 1 by iwcll criteria) Siddiqi T et al. ASH Abstract 300.
49 Conclusions Explosion of novel therapies for CLL in recent years, including monoclonal antibodies (like obinutuzumab), small molecule inhibitors of various kinases (like BTK and PI3K) and the antiapoptotic pathway (especially Bcl2), and CD19-specific CAR-T cells These novel, non-chemotherapeutic agents may do away with the need for standard chemoimmunotherapy in CLL, especially in older/unfit patients If chemo being considered for a patient, must check IGVH mutation status and FISH/cytogenetics first Combination studies are underway to improve outcomes further
50 COH CLL trials Ibrutinib + cirmtuzumab (frontline and rel/ref) Umbralisib + ublituximab + venetoclax (coming soon for rel/ref pts) Ibrutinib+obinutuzumab vs. ibrutinib+venetoclax+ obinutuzumab in pts >/= 70 yrs, previously untreated (coming soon) JCAR017 CAR-T cells (rel/ref, failed BTKi) COH CAR-T cells (any rel/ref)
Chronic lymphocytic leukemia
Chronic lymphocytic leukemia How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2018 Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA DISCLOSURES I am on
More informationChronic lymphocytic leukemia
Chronic lymphocytic leukemia Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2017 Disclosures Speaker
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationCLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic
CLL what do I need to know as an Internist in 218 Taimur Sher MD Associate Professor of Medicine Mayo Clinic Case 1 7 y/o white male for yearly medical evaluation Doing well and healthy Past medical history
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationManagement of 17p Deleted CLL Patients in the Era of Targeted Therapy
Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,
More informationChronic Lymphocytic Leukemia: State of the Art
14th Annual INDY Hematology Review March 2017 Chronic Lymphocytic Leukemia: State of the Art Adrian Wiestner, MD/PhD Bethesda, MD awiestner@hotmail.com Disclosures Grant/research support: Pharmacyclics
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationChronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances
Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances 2017 Master Class Course John C. Byrd, MD D Warren Brown Chair of Leukemia Research Distinguished University
More informationManagement of CLL in the Targeted Therapy Era
Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove
More informationChronic Lymphocytic Leukemia. Paolo Ghia
Chronic Lymphocytic Leukemia Paolo Ghia Complex Karyotype: a novel predictive marker? Thompson PA et al. Cancer 2015 Complex karyotype superseded del(17p) Anderson MA et al. Blood 2017 Ibrutinib and Idela
More informationLEUCEMIA LINFATICA CRONICA
LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: January, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: June, 2018 Copyright (2018) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved. This
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationManagement of Chronic Lymphatic Leukemia Beyond conventional therapy
3 rd Young Hematologists Orientation Program SGPGI Lucknow August 18 th -19 th 218 Management of Chronic Lymphatic Leukemia Beyond conventional therapy Prof. Hari Menon. MD DM Department of Hemato-Oncology
More informationCLL treatment algorithm and state of the art
CLL treatment algorithm and state of the art Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CLL subgroups
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationManagement of Patients With Relapsed Chronic Lymphocytic Leukemia
Management of Patients With Relapsed Chronic Lymphocytic Leukemia Polina Shindiapina, MD, PhD, and Farrukh T. Awan, MD Abstract The management of chronic lymphocytic leukemia (CLL) has improved significantly
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationDebate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy
Debate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy Steven Coutre, MD Stanford Cancer Institute William G. Wierda, MD, PhD The University
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Apply recent clinical research findings with the newly FDA-approved combination of obinutuzumab and chlorambucil to the management and care of patients with previously
More informationASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)
ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer
More informationCLL: Future Therapies. Dr. Anca Prica
CLL: Future Therapies Dr. Anca Prica Treatment Options: Improved by Decade 1960 1970 1980 1990 2000 2017 5% CR 5% CR Chemo Alkylator chlorambucil or cyclophosphamide 25% CR Chemo Purine analogues Fludarabine
More informationDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY 3
The Bruton s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Treatment Naïve (TN) Chronic Lymphocytic Leukemia (CLL) Patients: Interim Results of a Phase Ib/II Study
More informationWhat s on the Horizon for Chronic Lymphocytic Leukemia?
What s on the Horizon for Chronic Lymphocytic Leukemia? Matthew S. Davids, MD, MMSc Associate Director Center for Chronic Lymphocytic Leukemia Assistant Professor of Medicine Harvard Medical School Dana
More informationL approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro
L approccio terapeu-co Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro DISCLOSURE Nome: Maria Rosaria Cognome: Villa Impiego nell industria farmaceu7ca negli ul7mi 5 anni: NO Interssi
More informationQuando e se è possibile e u/le o0enere una remissione completa
Quando e se è possibile e u/le o0enere una remissione completa 1) Clinical heterogeneity Disease characteris:cs Pa:ent characteris:cs 2) Modern chemoimmunotherpy approaches 3) New mechanism- based treatment
More informationAktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation
Aktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation Dr. med. Petra Langerbeins Universitätsklinik Köln Deutsche CLL Studiengruppe (DCLLSG) OFFENLEGUNG
More informationDFCR. Dept. of Medical Oncology, Dana-Farber Cancer Institute 2. Dept. of Medical Oncology, Beth Israel Deaconess Medical Center Boston, USA
A Phase IB/II Study of Duvelisib in Combination with FCR (DFCR) For Frontline Therapy for Younger CLL Patients DFCR Matthew S. Davids, MD, MMSc 1, David C. Fisher, MD 1, Svitlana Tyekucheva, PhD 1, Haesook
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationIndustry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia
Industry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia Davy Chiodin with Nadia Ono Regulatory Science Acerta (A Member of the AstraZeneca Group) 09 November 2018 1
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationA CRP Breakout Session
A041202 CRP Breakout Session Jennifer Woyach, MD, A041202 Study Chair Samantha Sublett, A041202 Protocol Coordinator Luke Wilson, A041202 Data Manager Alliance Fall Group Meeting November 5, 2015 Agenda
More informationChronic Lymphocytic Leukemia: State of the Art
14th Annual INDY Hematology Review March 2017 Chronic Lymphocytic Leukemia: State of the Art Adrian Wiestner, MD/PhD Bethesda, MD awiestner@hotmail.com Disclosures Grant/research support: Pharmacyclics
More information15 th Annual Miami Cancer Meeting
15 th Annual Miami Cancer Meeting CLL and CML Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Director, Blood and Marrow Transplantation and Cellular Therapies Mayo Clinic Jacksonville, FL 15 th Annual Miami
More informationWelcome & Introductions
Living with Chronic Lymphocytic Leukemia (CLL) Welcome & Introductions Dr. Brander s slides are available for download at www.lls.org/programs Wednesday, July 12, 2017 1 Living with Chronic Lymphocytic
More informationLEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA
CORSO TEORICO-PRATICO PER LA GESTIONE OTTIMALE DEI PAZIENTI AFFETTI DA LINFOMA MANTELLARE, LINFOMA FOLLICOLARE E LEUCEMIA LINFATICA CRONICA Torino, 21-23 Maggio 2018 LEUCEMIA LINFATICA CRONICA: TERAPIA
More informationMedia Inquiries: Satu Glawe Phone: Bernadette King Phone:
Media Inquiries: Satu Glawe Phone: +49-172-294-6264 Bernadette King Phone: 1-215-778-3027 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationCLL: What s New from ASH
CLL: What s New from ASH John C. Byrd, MD D. Warren Brown Chair in Leukemia Research Professor of Medicine and Medicinal Chemistry Director, Division of Hematology The Ohio State University 2 Chronic Lymphocytic
More informationSequencing of chronic lymphocytic leukemia therapies
CHRONIC LYMPHOCYTIC LEUKEMIA Sequencing of chronic lymphocytic leukemia therapies Jacqueline C. Barrientos CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School
More informationRole of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia: From Clinical Data to Individualized Care Ryan Jacobs, MD
Role of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia: From Clinical Data to Individualized Care Ryan Jacobs, MD Department of Hematology Levine Cancer Institute Carolinas Health
More informationOutcomes of patients with CLL after discontinuing idelalisib
Outcomes of patients with CLL after discontinuing idelalisib Jacqueline C. Barrientos, Manmeen Kaur, Alexis Mark, Jaewon Chung, Nancy Driscoll, Alison Bender, Kanti R. Rai ASH Annual Meeting Abstracts
More informationRisikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL. Michael Hallek University of Cologne
Risikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL Michael Hallek University of Cologne 100 90 80 70 60 Substantial progress in CLL therapy in one decade 50 40 complete remissions
More informationChronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Received: 14 June 2017 Accepted: 15 June 2017 DOI: 10.1002/ajh.24826 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and
More informationTargeted Oncology Chronic Lymphocytic Leukemia Virtual Tumor Board
Targeted Oncology Chronic Lymphocytic Leukemia Virtual Tumor Board Segment 1 Segment Title: Case 1: An Elderly Patient With Newly Diagnosed High-Risk CLL Segment Description: William Wierda, MD, PhD, and
More informationEmerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia
Emerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia This educational activity is supported by an educational grant from AbbVie Faculty Jennifer R Brown, MD PhD
More informationAdvances in the treatment of Chronic Lymphocytic Leukemia
Advances in the treatment of Chronic Lymphocytic Leukemia Lab of B Cell Neoplasia - Division of Experimental Oncology Strategic Research Program on CLL Department of Onco-Hematology Università Vita-Salute
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationChronic Lymphocytic Leukemia: Current Concepts
Review Chronic Lymphocytic Leukemia: Current Concepts EUN-MI YU 1, ADAM KITTAI 2 and IMAD A. TABBARA 1 1 Department of Hematology/ Oncology, George Washington University, Washington, DC, U.S.A.; 2 Department
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018
pan-canadian Oncology Drug Review Final Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationChronic Lymphocytic Leukaemia and Its Challenges for Insurers
Chronic Lymphocytic Leukaemia and Its Challenges for Insurers Sheetal Salgaonkar, M.D. Medical Director RGA Services India Private Limited Chronic lymphocytic leukaemia (CLL) is a slow-developing cancer
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationMED B Form CLL. Johannes Schetelig. London 09/April/
www.ebmt.org MED B Form CLL Johannes Schetelig London 09/April/2013 Content Update on CLL (15 ) Experiment with mini MED B CLL Assessment of pre-treatment in CLL Cytogenetics in CLL What is the IGVH-Gene
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationPost-ASH 2015 Chronic Lymphocytic Leukaemia. Anna Schuh Consultant Haematologist Oxford
Post-ASH 2015 Chronic Lymphocytic Leukaemia Anna Schuh Consultant Haematologist Oxford NEWS IN FRONT-LINE Consort Diagram CLL10 Study: FCR VS BR in Front-line 688 CLL patients screened centrally for: immunophenotype
More informationVENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth
VENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth ABT-199 Venetoclax ABT-199 is a selective, potent, orally
More informationCLL: State of the Art 2018
CLL: State of the Art 2018 Dr. Susan O Brien, MD Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue and Ralph Stern Center for Cancer Clinical Trials
More informationInvestigation and Management of Chronic Lymphocytic Leukemia. James Johnston
Investigation and Management of Chronic Lymphocytic Leukemia James Johnston Site Specific Clinics CLL Clinic (787-4454) Erin Elphee BN James Johnston Rajat Kumar Matt Seftel (transplant) Myeloma Clinic
More information1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationThe International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist. Other Advances in Leukemia/MDS ALL AML MDS
The Oncologist The International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist Peer-Reviewed Journal for the Practicing Oncologist/Hematologist 20 th Anniversary Overview
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationConstan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia
Constan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia BGB-3111: Kinase Selec.vity Rela.ve to Ibru.nib Equipotent against BTK compared to ibru.nib Higher selec.vity vs EGFR, ITK, JAK3,
More informationREAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA.
REAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA Roberta Murru Struttura Complessa Ematologia e Centro Trapianti Presidio Ospedaliero
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationLeukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington
Leukemia Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center University of Washington Discussed Abstracts Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody
More informationDefining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia
Defining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia Mollie Moran, CNP The James Cancer Hospital at The Ohio State University Jeffrey Jones, MD/MPH Ohio State University Comprehensive
More informationShort Telomeres Predict Poor Prognosis in Chronic Lymphocytic Leukemia
Short Telomeres Predict Poor Prognosis in Chronic Lymphocytic Leukemia L. Yang Internal Medicine Resident University of Manitoba Supervisor: Dr. J. Johnston Prognostic factors Clinical course is unpredictable
More informationTolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL
Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced and NHL Loretta Nastoupil, MD 1, Matthew A. Lunning, DO 2, Julie
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationREPORT SUMMARY. of a Health Technology Assessment. under art. 17, paragraph 7 of Regulation 9 from Dec. 01, 2015
REPORT SUMMARY of a Health Technology Assessment under art. 17, paragraph 7 of Regulation 9 from Dec. 01, 2015 of the Ministry of Health of the Republic of Bulgaria For the medicinal product Venclyxto
More informationChronic lymphocytic leukemia. E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015
Chronic lymphocytic leukemia E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015 Disclosures Travelling to ASH: Roche Consulting services: Janssen Questions in CLL: answers
More informationUNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL. June 6, 2018
UNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL June 6, 2018 0 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Review patient heterogeneity and its connection to unmet needs Explore unmet needs within the CLL/SLL
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More information